Department of Visceral Surgery, Lausanne University Hospital CHUV, Lausanne, Switzerland.
Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India.
J Gastrointest Cancer. 2021 Sep;52(3):1061-1066. doi: 10.1007/s12029-020-00538-1. Epub 2020 Oct 19.
Patients with peritoneal carcinomatosis (PC) are increasingly treated with multidisciplinary combined approaches. The study aim was to assess current practice and perceptions of treatment modalities of PC.
Indian Society of Peritoneal Surface Malignancies (ISPSM) members were invited to complete an online survey. Current practice and perceptions of treatment modalities were assessed through 19 closed questions. Scores were assessed using a Likert scale (0: not important, 5: very important). Treatment modality satisfaction was assessed using a semantic scale (frustrated: 0, perfectly happy: 10). Participants were sent 3 reminders at 4-week intervals.
Fifty-seven out of 182 members completed the survey (31%). Forty percent of participants had an experience of at least 10 years, and 75% stated treating less than 20 PC patients per year. Main treatment goals for patients with PC were cure (5/5) and symptom relief (4/5). Participant's satisfaction with treatment modalities for ovarian, colorectal, and gastric PC were 6/10, 5/10, and 2/10, respectively. Hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian (57%) and colorectal (44%) origins were considered to be useful. Clinical usefulness of chemotherapy for gastric PC was rated to be low (17%).
Current treatment modalities fall short to satisfy the needs (cure, symptom relief) of patients with PC. Alternative systemic and intraperitoneal treatment modalities should be assessed.
越来越多的腹膜癌转移（PC）患者接受多学科联合治疗。本研究旨在评估目前对 PC 治疗方式的实践和看法。
邀请印度腹膜表面恶性肿瘤学会（ISPSM）成员完成在线调查。通过 19 个封闭问题评估当前的治疗方法和对治疗方式的看法。采用李克特量表（0：不重要，5：非常重要）评估分数。治疗方式满意度采用语义量表评估（沮丧：0，非常满意：10）。参与者每 4 周收到 3 次提醒。
182 名成员中有 57 名完成了调查（31%）。40%的参与者有至少 10 年的经验，75%的参与者每年治疗的 PC 患者少于 20 人。PC 患者的主要治疗目标是治愈（5/5）和缓解症状（4/5）。参与者对卵巢、结直肠和胃 PC 的治疗方式满意度分别为 6/10、5/10 和 2/10。对于卵巢（57%）和结直肠（44%）来源的 HIPEC 被认为是有用的。对于胃 PC 的化疗临床有用性的评价较低（17%）。
目前的治疗方法未能满足 PC 患者的需求（治愈、缓解症状）。应评估替代的全身和腹腔内治疗方法。
